{"id":62228,"date":"2025-11-19T04:05:42","date_gmt":"2025-11-19T03:05:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/"},"modified":"2025-11-19T04:05:42","modified_gmt":"2025-11-19T03:05:42","slug":"yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/","title":{"rendered":"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)"},"content":{"rendered":"
\n

SHANGHAI–(BUSINESS WIRE)–YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for YOLT-203<\/b>, an in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1).<\/b><\/p>\n

<\/a>
<\/a><\/p>\n

\nThe global multicenter, randomized, double-blind, placebo-controlled study is the first pivotal trial of an in vivo gene-editing therapy for PH1<\/b>, aiming to evaluate the safety and efficacy of YOLT-203 in reducing urinary oxalate levels and improving long-term renal outcomes.<\/p>\n

\nYOLT-203 has also received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA, as well as Orphan Drug Designation from the European Medicines Agency (EMA).<\/p>\n

\nAbout YOLT-203<\/span><\/b><\/p>\n

\nYOLT-203 is an investigational in vivo gene-editing therapy designed to be a once-and-done treatment for PH1, a rare genetic disorder that leads to recurrent kidney stone formation and progress to kidney failure. The therapy aims to reduce the oxalate overproduction in PH1 patients by deactivating glycolate oxidase (GO), an enzyme encoded by HAO1 gene and suppressing the synthesis of oxalate precursors.<\/p>\n

\nAbout YolTech<\/span><\/b><\/p>\n

\nBuilt on next-generation CRISPR\/Cas and LNP technologies, YolTech Therapeutics is pioneering in vivo gene-editing medicines with the potential for one-time, lifelong benefit. The company\u2019s expanding clinical pipeline targets genetic, metabolic, cardiovascular, and autoimmune diseases, with initial results supporting the potential for durable and transformative therapeutic benefit.<\/p>\n

\nStay informed with the latest from YolTech Therapeutics:
\n
LinkedIn: linkedin.com\/company\/yoltech-therapeutics
\n
Website: <\/strong>www.yoltx.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nYolTech Therapeutics
\n
Ally Yu
\n
xiaolingyu@yoltx.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SHANGHAI–(BUSINESS WIRE)–YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for YOLT-203, an in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). The global multicenter, randomized, double-blind, placebo-controlled … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62228","6":"format-standard","7":"category-industry"},"yoast_head":"\nYolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI–(BUSINESS WIRE)–YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for YOLT-203, an in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). The global multicenter, randomized, double-blind, placebo-controlled ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-19T03:05:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251117980866\/en\/2647482\/22\/YolTech_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)\",\"datePublished\":\"2025-11-19T03:05:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/\"},\"wordCount\":282,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117980866\\\/en\\\/2647482\\\/22\\\/YolTech_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/\",\"name\":\"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117980866\\\/en\\\/2647482\\\/22\\\/YolTech_Logo.jpg\",\"datePublished\":\"2025-11-19T03:05:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117980866\\\/en\\\/2647482\\\/22\\\/YolTech_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251117980866\\\/en\\\/2647482\\\/22\\\/YolTech_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/","og_locale":"en_US","og_type":"article","og_title":"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1) - Pharma Trend","og_description":"SHANGHAI–(BUSINESS WIRE)–YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company\u2019s Investigational New Drug (IND) application for YOLT-203, an in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1). The global multicenter, randomized, double-blind, placebo-controlled ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/","og_site_name":"Pharma Trend","article_published_time":"2025-11-19T03:05:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251117980866\/en\/2647482\/22\/YolTech_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)","datePublished":"2025-11-19T03:05:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/"},"wordCount":282,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251117980866\/en\/2647482\/22\/YolTech_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/","url":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/","name":"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251117980866\/en\/2647482\/22\/YolTech_Logo.jpg","datePublished":"2025-11-19T03:05:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251117980866\/en\/2647482\/22\/YolTech_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251117980866\/en\/2647482\/22\/YolTech_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-editing-therapy-yolt-203-for-primary-hyperoxaluria-type-1-ph1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"YolTech Therapeutics Receives FDA IND Clearance to Initiate Global Pivotal Trial of In Vivo Gene-Editing Therapy YOLT-203 for Primary Hyperoxaluria Type 1 (PH1)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62228"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62228\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}